Loading…

Antilipase and antiproliferative activities of novel fluoroquinolones and triazolofluoroquinolones

Fluoroquinolones (FQs) have been identified recently as potent inhibitors of pancreatic lipase (PL). The aim of this study was to synthesize novel FQs and triazolofluoroquinolones (TFQs) and to evaluate them in vitro with respect to their antilipolytic efficacy and potency properties. The PL‐IC50 va...

Full description

Saved in:
Bibliographic Details
Published in:Chemical biology & drug design 2017-12, Vol.90 (6), p.1282-1294
Main Authors: Arabiyat, Shereen, Kasabri, Violet, Al‐Hiari, Yusuf, Bustanji, Yasser K., Albashiti, Rabab, Almasri, Ihab M., Sabbah, Dima A.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3299-277b7a0e8c918aac0bf2643c894173af1e4b6656671faadd764408e8fba99c63
cites cdi_FETCH-LOGICAL-c3299-277b7a0e8c918aac0bf2643c894173af1e4b6656671faadd764408e8fba99c63
container_end_page 1294
container_issue 6
container_start_page 1282
container_title Chemical biology & drug design
container_volume 90
creator Arabiyat, Shereen
Kasabri, Violet
Al‐Hiari, Yusuf
Bustanji, Yasser K.
Albashiti, Rabab
Almasri, Ihab M.
Sabbah, Dima A.
description Fluoroquinolones (FQs) have been identified recently as potent inhibitors of pancreatic lipase (PL). The aim of this study was to synthesize novel FQs and triazolofluoroquinolones (TFQs) and to evaluate them in vitro with respect to their antilipolytic efficacy and potency properties. The PL‐IC50 values of 12 FQs and TFQs (3 (a–c)–6 (a–c)) were in the range of 12.5–189.1 μm. These values are further supported by docking studies. The suggested association between obesity and colorectal cancer initiated the evaluation of antiproliferative activity of the new FQs and TFQs against a panel of obesity‐related colorectal cells (HT29, HCT116, SW620 CACO2, and SW480). Sulforodamine B colorimetric assay revealed that some derivatives exhibited unselective cytotoxicity against HT29, HCT116, SW620 CACO2, and SW480. Remarkably, FQ 4a's selective cytotoxicity against HCT116 was found valuable with IC50 value of 4.2 μm which exceeds that of cisplatin with a substantial selective cytotoxicity in periodontal ligament fibroblasts. In conclusion, FQ and TFQ derivatives may unveil new antiobesity and anticancer agents in the future. Novel FQs and TFQs are synthesized and evaluated in vitro with respect to their antilipolytic and antiproliferative efficacy and potency properties. The PL‐IC50 values of 12 FQs and TFQs (3 (a–c)–6 (a–c)) were in the range of 12.5–189.1 μm. FQ 4a's selective cytotoxicity against HCT116 was found valuable with IC50 value of 4.2 μm which exceeds that of cisplatin.
doi_str_mv 10.1111/cbdd.13049
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1912615744</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1912615744</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3299-277b7a0e8c918aac0bf2643c894173af1e4b6656671faadd764408e8fba99c63</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EoqWw4QNQlggpxU4cP5al5SVVYtO95Ti2ZOTGIU6KytfjkNIFC0ayZjxz5tq6AFwjOEcx7lVZVXOUQ8xPwBRRTFOYseL0WFM6ARchvEOIcZGxczDJGMl5XrApKBd1Z51tZNCJrKt4Otu03lmjW9nZXeyqmGxndUi8SWq_0y4xrvet_-ht7Z2v42RY7Vorv-L97_ASnBnpgr465BnYPD1uli_p-u35dblYpyrPOE_jN0sqoWaKIyalgqXJCM4V4xjRXBqkcUlIQQhFRsqqogRjyDQzpeRckXwGbkfZZnhch05sbVDaOVlr3weBOMoIKijGEb0bUdX6EFptRNParWz3AkExWCoGS8WPpRG-Oej25VZXR_TXwwigEfi0Tu__kRLLh9VqFP0GfYuECg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1912615744</pqid></control><display><type>article</type><title>Antilipase and antiproliferative activities of novel fluoroquinolones and triazolofluoroquinolones</title><source>Wiley</source><creator>Arabiyat, Shereen ; Kasabri, Violet ; Al‐Hiari, Yusuf ; Bustanji, Yasser K. ; Albashiti, Rabab ; Almasri, Ihab M. ; Sabbah, Dima A.</creator><creatorcontrib>Arabiyat, Shereen ; Kasabri, Violet ; Al‐Hiari, Yusuf ; Bustanji, Yasser K. ; Albashiti, Rabab ; Almasri, Ihab M. ; Sabbah, Dima A.</creatorcontrib><description>Fluoroquinolones (FQs) have been identified recently as potent inhibitors of pancreatic lipase (PL). The aim of this study was to synthesize novel FQs and triazolofluoroquinolones (TFQs) and to evaluate them in vitro with respect to their antilipolytic efficacy and potency properties. The PL‐IC50 values of 12 FQs and TFQs (3 (a–c)–6 (a–c)) were in the range of 12.5–189.1 μm. These values are further supported by docking studies. The suggested association between obesity and colorectal cancer initiated the evaluation of antiproliferative activity of the new FQs and TFQs against a panel of obesity‐related colorectal cells (HT29, HCT116, SW620 CACO2, and SW480). Sulforodamine B colorimetric assay revealed that some derivatives exhibited unselective cytotoxicity against HT29, HCT116, SW620 CACO2, and SW480. Remarkably, FQ 4a's selective cytotoxicity against HCT116 was found valuable with IC50 value of 4.2 μm which exceeds that of cisplatin with a substantial selective cytotoxicity in periodontal ligament fibroblasts. In conclusion, FQ and TFQ derivatives may unveil new antiobesity and anticancer agents in the future. Novel FQs and TFQs are synthesized and evaluated in vitro with respect to their antilipolytic and antiproliferative efficacy and potency properties. The PL‐IC50 values of 12 FQs and TFQs (3 (a–c)–6 (a–c)) were in the range of 12.5–189.1 μm. FQ 4a's selective cytotoxicity against HCT116 was found valuable with IC50 value of 4.2 μm which exceeds that of cisplatin.</description><identifier>ISSN: 1747-0277</identifier><identifier>EISSN: 1747-0285</identifier><identifier>DOI: 10.1111/cbdd.13049</identifier><identifier>PMID: 28639358</identifier><language>eng</language><publisher>England</publisher><subject>Antineoplastic Agents - chemical synthesis ; Antineoplastic Agents - chemistry ; Antineoplastic Agents - pharmacology ; Binding Sites ; Caco-2 Cells ; Catalytic Domain ; Cell Line, Tumor ; Cell Survival - drug effects ; colorectal cancer ; fluoroquinolones ; Fluoroquinolones - chemical synthesis ; Fluoroquinolones - chemistry ; Fluoroquinolones - pharmacology ; Humans ; Hydrogen Bonding ; Inhibitory Concentration 50 ; Molecular Docking Simulation ; pancreatic triacylglycerol lipase ; Pancrelipase - antagonists &amp; inhibitors ; Pancrelipase - metabolism ; Structure-Activity Relationship ; Thermodynamics ; triazolofluoroquinolones</subject><ispartof>Chemical biology &amp; drug design, 2017-12, Vol.90 (6), p.1282-1294</ispartof><rights>2017 John Wiley &amp; Sons A/S</rights><rights>2017 John Wiley &amp; Sons A/S.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3299-277b7a0e8c918aac0bf2643c894173af1e4b6656671faadd764408e8fba99c63</citedby><cites>FETCH-LOGICAL-c3299-277b7a0e8c918aac0bf2643c894173af1e4b6656671faadd764408e8fba99c63</cites><orcidid>0000-0001-7456-2848 ; 0000-0003-1428-5097</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28639358$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Arabiyat, Shereen</creatorcontrib><creatorcontrib>Kasabri, Violet</creatorcontrib><creatorcontrib>Al‐Hiari, Yusuf</creatorcontrib><creatorcontrib>Bustanji, Yasser K.</creatorcontrib><creatorcontrib>Albashiti, Rabab</creatorcontrib><creatorcontrib>Almasri, Ihab M.</creatorcontrib><creatorcontrib>Sabbah, Dima A.</creatorcontrib><title>Antilipase and antiproliferative activities of novel fluoroquinolones and triazolofluoroquinolones</title><title>Chemical biology &amp; drug design</title><addtitle>Chem Biol Drug Des</addtitle><description>Fluoroquinolones (FQs) have been identified recently as potent inhibitors of pancreatic lipase (PL). The aim of this study was to synthesize novel FQs and triazolofluoroquinolones (TFQs) and to evaluate them in vitro with respect to their antilipolytic efficacy and potency properties. The PL‐IC50 values of 12 FQs and TFQs (3 (a–c)–6 (a–c)) were in the range of 12.5–189.1 μm. These values are further supported by docking studies. The suggested association between obesity and colorectal cancer initiated the evaluation of antiproliferative activity of the new FQs and TFQs against a panel of obesity‐related colorectal cells (HT29, HCT116, SW620 CACO2, and SW480). Sulforodamine B colorimetric assay revealed that some derivatives exhibited unselective cytotoxicity against HT29, HCT116, SW620 CACO2, and SW480. Remarkably, FQ 4a's selective cytotoxicity against HCT116 was found valuable with IC50 value of 4.2 μm which exceeds that of cisplatin with a substantial selective cytotoxicity in periodontal ligament fibroblasts. In conclusion, FQ and TFQ derivatives may unveil new antiobesity and anticancer agents in the future. Novel FQs and TFQs are synthesized and evaluated in vitro with respect to their antilipolytic and antiproliferative efficacy and potency properties. The PL‐IC50 values of 12 FQs and TFQs (3 (a–c)–6 (a–c)) were in the range of 12.5–189.1 μm. FQ 4a's selective cytotoxicity against HCT116 was found valuable with IC50 value of 4.2 μm which exceeds that of cisplatin.</description><subject>Antineoplastic Agents - chemical synthesis</subject><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Binding Sites</subject><subject>Caco-2 Cells</subject><subject>Catalytic Domain</subject><subject>Cell Line, Tumor</subject><subject>Cell Survival - drug effects</subject><subject>colorectal cancer</subject><subject>fluoroquinolones</subject><subject>Fluoroquinolones - chemical synthesis</subject><subject>Fluoroquinolones - chemistry</subject><subject>Fluoroquinolones - pharmacology</subject><subject>Humans</subject><subject>Hydrogen Bonding</subject><subject>Inhibitory Concentration 50</subject><subject>Molecular Docking Simulation</subject><subject>pancreatic triacylglycerol lipase</subject><subject>Pancrelipase - antagonists &amp; inhibitors</subject><subject>Pancrelipase - metabolism</subject><subject>Structure-Activity Relationship</subject><subject>Thermodynamics</subject><subject>triazolofluoroquinolones</subject><issn>1747-0277</issn><issn>1747-0285</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kMtOwzAQRS0EoqWw4QNQlggpxU4cP5al5SVVYtO95Ti2ZOTGIU6KytfjkNIFC0ayZjxz5tq6AFwjOEcx7lVZVXOUQ8xPwBRRTFOYseL0WFM6ARchvEOIcZGxczDJGMl5XrApKBd1Z51tZNCJrKt4Otu03lmjW9nZXeyqmGxndUi8SWq_0y4xrvet_-ht7Z2v42RY7Vorv-L97_ASnBnpgr465BnYPD1uli_p-u35dblYpyrPOE_jN0sqoWaKIyalgqXJCM4V4xjRXBqkcUlIQQhFRsqqogRjyDQzpeRckXwGbkfZZnhch05sbVDaOVlr3weBOMoIKijGEb0bUdX6EFptRNParWz3AkExWCoGS8WPpRG-Oej25VZXR_TXwwigEfi0Tu__kRLLh9VqFP0GfYuECg</recordid><startdate>201712</startdate><enddate>201712</enddate><creator>Arabiyat, Shereen</creator><creator>Kasabri, Violet</creator><creator>Al‐Hiari, Yusuf</creator><creator>Bustanji, Yasser K.</creator><creator>Albashiti, Rabab</creator><creator>Almasri, Ihab M.</creator><creator>Sabbah, Dima A.</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7456-2848</orcidid><orcidid>https://orcid.org/0000-0003-1428-5097</orcidid></search><sort><creationdate>201712</creationdate><title>Antilipase and antiproliferative activities of novel fluoroquinolones and triazolofluoroquinolones</title><author>Arabiyat, Shereen ; Kasabri, Violet ; Al‐Hiari, Yusuf ; Bustanji, Yasser K. ; Albashiti, Rabab ; Almasri, Ihab M. ; Sabbah, Dima A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3299-277b7a0e8c918aac0bf2643c894173af1e4b6656671faadd764408e8fba99c63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Antineoplastic Agents - chemical synthesis</topic><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Binding Sites</topic><topic>Caco-2 Cells</topic><topic>Catalytic Domain</topic><topic>Cell Line, Tumor</topic><topic>Cell Survival - drug effects</topic><topic>colorectal cancer</topic><topic>fluoroquinolones</topic><topic>Fluoroquinolones - chemical synthesis</topic><topic>Fluoroquinolones - chemistry</topic><topic>Fluoroquinolones - pharmacology</topic><topic>Humans</topic><topic>Hydrogen Bonding</topic><topic>Inhibitory Concentration 50</topic><topic>Molecular Docking Simulation</topic><topic>pancreatic triacylglycerol lipase</topic><topic>Pancrelipase - antagonists &amp; inhibitors</topic><topic>Pancrelipase - metabolism</topic><topic>Structure-Activity Relationship</topic><topic>Thermodynamics</topic><topic>triazolofluoroquinolones</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arabiyat, Shereen</creatorcontrib><creatorcontrib>Kasabri, Violet</creatorcontrib><creatorcontrib>Al‐Hiari, Yusuf</creatorcontrib><creatorcontrib>Bustanji, Yasser K.</creatorcontrib><creatorcontrib>Albashiti, Rabab</creatorcontrib><creatorcontrib>Almasri, Ihab M.</creatorcontrib><creatorcontrib>Sabbah, Dima A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Chemical biology &amp; drug design</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arabiyat, Shereen</au><au>Kasabri, Violet</au><au>Al‐Hiari, Yusuf</au><au>Bustanji, Yasser K.</au><au>Albashiti, Rabab</au><au>Almasri, Ihab M.</au><au>Sabbah, Dima A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antilipase and antiproliferative activities of novel fluoroquinolones and triazolofluoroquinolones</atitle><jtitle>Chemical biology &amp; drug design</jtitle><addtitle>Chem Biol Drug Des</addtitle><date>2017-12</date><risdate>2017</risdate><volume>90</volume><issue>6</issue><spage>1282</spage><epage>1294</epage><pages>1282-1294</pages><issn>1747-0277</issn><eissn>1747-0285</eissn><abstract>Fluoroquinolones (FQs) have been identified recently as potent inhibitors of pancreatic lipase (PL). The aim of this study was to synthesize novel FQs and triazolofluoroquinolones (TFQs) and to evaluate them in vitro with respect to their antilipolytic efficacy and potency properties. The PL‐IC50 values of 12 FQs and TFQs (3 (a–c)–6 (a–c)) were in the range of 12.5–189.1 μm. These values are further supported by docking studies. The suggested association between obesity and colorectal cancer initiated the evaluation of antiproliferative activity of the new FQs and TFQs against a panel of obesity‐related colorectal cells (HT29, HCT116, SW620 CACO2, and SW480). Sulforodamine B colorimetric assay revealed that some derivatives exhibited unselective cytotoxicity against HT29, HCT116, SW620 CACO2, and SW480. Remarkably, FQ 4a's selective cytotoxicity against HCT116 was found valuable with IC50 value of 4.2 μm which exceeds that of cisplatin with a substantial selective cytotoxicity in periodontal ligament fibroblasts. In conclusion, FQ and TFQ derivatives may unveil new antiobesity and anticancer agents in the future. Novel FQs and TFQs are synthesized and evaluated in vitro with respect to their antilipolytic and antiproliferative efficacy and potency properties. The PL‐IC50 values of 12 FQs and TFQs (3 (a–c)–6 (a–c)) were in the range of 12.5–189.1 μm. FQ 4a's selective cytotoxicity against HCT116 was found valuable with IC50 value of 4.2 μm which exceeds that of cisplatin.</abstract><cop>England</cop><pmid>28639358</pmid><doi>10.1111/cbdd.13049</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0001-7456-2848</orcidid><orcidid>https://orcid.org/0000-0003-1428-5097</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1747-0277
ispartof Chemical biology & drug design, 2017-12, Vol.90 (6), p.1282-1294
issn 1747-0277
1747-0285
language eng
recordid cdi_proquest_miscellaneous_1912615744
source Wiley
subjects Antineoplastic Agents - chemical synthesis
Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacology
Binding Sites
Caco-2 Cells
Catalytic Domain
Cell Line, Tumor
Cell Survival - drug effects
colorectal cancer
fluoroquinolones
Fluoroquinolones - chemical synthesis
Fluoroquinolones - chemistry
Fluoroquinolones - pharmacology
Humans
Hydrogen Bonding
Inhibitory Concentration 50
Molecular Docking Simulation
pancreatic triacylglycerol lipase
Pancrelipase - antagonists & inhibitors
Pancrelipase - metabolism
Structure-Activity Relationship
Thermodynamics
triazolofluoroquinolones
title Antilipase and antiproliferative activities of novel fluoroquinolones and triazolofluoroquinolones
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T07%3A44%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antilipase%20and%20antiproliferative%20activities%20of%20novel%20fluoroquinolones%20and%20triazolofluoroquinolones&rft.jtitle=Chemical%20biology%20&%20drug%20design&rft.au=Arabiyat,%20Shereen&rft.date=2017-12&rft.volume=90&rft.issue=6&rft.spage=1282&rft.epage=1294&rft.pages=1282-1294&rft.issn=1747-0277&rft.eissn=1747-0285&rft_id=info:doi/10.1111/cbdd.13049&rft_dat=%3Cproquest_cross%3E1912615744%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3299-277b7a0e8c918aac0bf2643c894173af1e4b6656671faadd764408e8fba99c63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1912615744&rft_id=info:pmid/28639358&rfr_iscdi=true